Abstract. Clinically inapparent adrenal masses, or adrenal incidentalomas, are discovered inadvertently in the course of workup or treatment of unrelated disorders. Cortical adenoma is the most frequent type of adrenal incidentaloma accounting for approximately 50% of cases in surgical series and even greater shares in medical series. Incidentally discovered adrenal adenomas may secrete cortisol in an autonomous manner, that is not fully restrained by pituitary feed-back, in 5 to 20% of cases depending on study protocols and diagnostic criteria. A number of different alterations in the endocrine tests aimed to assess the function of the hypothalamic-pituitaryadrenal axis has been demonstrated in such patients. This heterogeneous condition has been termed as subclinical Cushing's syndrome, a definition that is more accurate than preclinical Cushing's syndrome since the evolution towards clinically overt hypercortisolism does occur rarely, if ever. The criteria for qualifying subclinical cortisol excess are controversial and we presently do not have sufficient evidence to define a gold standard for the diagnosis of subclinical Cushing's syndrome. An increased frequency of hypertension, central obesity, impaired glucose tolerance, diabetes and hyperlipoproteinemia has been described in patients with subclinical Cushing's syndrome; however, there is not evidence-based demonstration of its long-term complications and, consequently, the management of this condition is largely empirical. Either adrenalectomy or careful observation associated with treatment of metabolic syndrome has been suggested as treatment options because data are insufficient to indicate the superiority of a surgical or nonsurgical approach to manage patients with subclinical hyperfunctioning adrenal cortical adenomas.
Introduction
In the heyday of high-tech medicine the serendipitous discovery of an adrenal mass is become a frequent event owing to the routine use of sophisticated radiological techniques. Clinically inapparent adrenal masses, or adrenal incidentalomas, are discovered inadvertently in the course of workup or treatment of unrelated disorders [1] [2] [3] . Adrenal incidentaloma is not a uniform disease; it rather includes a spectrum of different pathological entities sharing the same way of discovery. Cortical adenoma is the most frequent type of adrenal incidentaloma accounting for approximately 50% of cases in surgical series and even greater shares in medical series [4] (Fig. 1) . Appropriate management of adrenal incidentaloma is a growing public health challenge since the serendipitous detection of an adrenal mass increases with age ( Fig. 2 ) and is expected to rise in populations that are getting older and may have widespread access to ever improving radiological techniques [5] .
Incidentally discovered adrenal adenomas may secrete cortisol in an autonomous manner, that is not fully restrained by pituitary feed-back, in 5 to 20% of cases depending on study protocols and diagnostic criteria. A number of different alterations in the endocrine tests aimed to assess the function of the hypothalamicpituitary-adrenal (HPA) axis has been demonstrated in such patients [2, [6] [7] [8] [9] [10] [11] [12] . This heterogeneous condition has been termed as subclinical Cushing's syndrome [13] , a definition that is more accurate than preclinical Cushing's syndrome since the evolution towards clinically overt hypercortisolism does occur rarely, if ever [14] [15] [16] [17] .
Diagnosis
Subclinical Cushing's syndrome does occur in patients bearing clinically nonfunctioning adrenal adenoma ( Fig. 3 ) that secretes cortisol autonomously and, possibly, in excess. The heart of the problem is to understand whether autonomy is associated with hypersecretion of cortisol but this aim is extremely difficult to pursue for several reasons.
First, the standard biochemical tests used to screen for overt Cushing's syndrome are generally ill-suited to the assessment of patients who have no, or only very mild, signs of cortisol excess [13, 15] . By definition, patients with incidentally discovered adrenal ade- noma do not present with overt physical signs of Cushing's syndrome and in this clinical setting it is hard distinguishing between subclinical hypercortisolism and false-positivity of the test. The frequency of subclinical Cushing's syndrome among patients with adrenal incidentaloma is indeed roughly comparable with the known false-positive rate of the tests used in the screening [13, 15] .
Second, many tests aimed to study the HPA axis do not have sufficient sensitivity to recognize very mild degrees of cortisol excess, as is the case with urinary free cortisol (UFC) excretion measured by immunoassays that are influenced by various metabolites of cortisol. Moreover, the output of UFC may show a remarkable daily variation that is further amplified by difficulties in obtaining complete urine collections [18] .
Third, many hormonal assays do not have sufficient accuracy when working at the ends of the normal range. The pitfalls encountered in differentiat- ing ACTH-dependent from ACTH-independent Cushing's syndrome even in the era of immunoradiometric ACTH assays represent a pertinent example of laboratory shortcoming [19] . The model of thyrotropin measurement in the diagnostic approach to autonomously functioning thyroid nodule is inapplicable to adrenal incidentaloma since ACTH measurement cannot be relied on to detect a minimal excess of cortisol production.
Functional autonomy of clinically inapparent adrenal adenomas may be depicted in vivo by iodocholesterol scintigraphy showing a typical imaging pattern of unilateral tracer uptake in the adenoma and absent uptake in the contralateral adrenal gland [1, [20] [21] [22] . However, it is unlikely that adrenal scintigraphy may represent a helpful method to detect subclinical Cushing's syndrome in the clinical practice since NP-59 uptake by an adrenal adenoma does occur even in the absence of alterations in the biochemical tests [8, 23] . The specificity of this finding has been questioned as it was argued that increased uptake merely reflects the presence of enlarged adrenal tissue [23, 24] . Moreover, adrenal scintigraphy is a cumbersome and expensive technique that is not widely available; thus, its use has not gained general acceptance outside a research setting.
Methodological problems add to biologic variability of silent (subclinical) cortisol excess thus render- ing this condition very difficult to characterize. Subclinical cortisol hypersecretion varies according to a continuum and an extensive endocrine workup may provide such a spectrum of results that it is difficult to define the entity of cortisol excess necessary to assume subclinical Cushing's syndrome (Fig. 4 ). This spectrum of variability from normality over autonomy has been outlined in a previous report of our group that categorized patients as having "definite", "probable" and "possible" subclinical Cushing's syndrome according to the outcome of screening tests [8] . It is therefore hardly surprising that the criteria for qualifying subclinical cortisol excess are controversial [14, 15, 17] . The analysis of the relevant literature should be done taking into consideration that various endocrine algorithms (testing methods) with disparate thresholds have been used across different series that are also heterogeneous as to sample size and inclusion criteria [1] [2] [3] [4] [6] [7] [8] [9] [10] [11] [12] 14, 15, 17] . The bottom line is that we presently do not have sufficient evidence to define a gold standard for the diagnosis of subclinical Cushing's syndrome.
A blunted circadian rhythm of cortisol has been frequently reported despite normal morning cortisol levels [6, 8, 9, 23] . Increase in UFC excretion has been less frequently found [7, 8, 12, 14, 15] in agreement with the view that measurement of UFC has insufficient sensitivity to detect mild hypercortisolism [18] . Cortisol excess might be minimal but sufficient to suppress ACTH secretion, as low to undetectable ACTH levels have been repeatedly reported in clinically inapparent adrenal tumors [6] [7] [8] [9] [10] [11] . Technical problems with measurement of ACTH concentrations close to the detection limits of the assay affect the utility of ACTH determination to demonstrate functional autonomy of the adrenal adenoma [18, 19] . It has been suggested that reduction in dehydroepiandrosterone sulfate (DHEAS) concentration may serve as an indicator of HPA axis suppression [23, 25] . Nevertheless, recent studies have casted doubts on the sensitivity of DHEAS as a predictor of hormonal activity [26, 27] .
Dexamethasone suppression tests have been extensively employed to screen for subclinical hypercortisolism in patients with adrenal incidentaloma but results of different studies are not readily comparable since various amounts of dexamethasone and different thresholds of suppression have been used [15] . To provide a standard, the NIH state-of-the-science conference panel recommended the 1-mg dexamethasone suppression test to screen for autonomous cortisol secretion with the traditional threshold of 5 µg/dL (138 nmol/L) to define adequate suppression [2] . However, some experts have proposed to use lower cutpoints to increase the detection of subclinical hypercortisolism [28] . The rationale for this choice is that in most healthy subjects cortisol is barely detectable following 1 mg dexamethasone [28, 29] . However, specificity decreases when lower post-dexamethasone cortisol thresholds are used, which may result in more false positive test results; thus, other authors have suggested to employ high-dose dexamethasone tests (3 or even 8 mg) since the diagnosis of pituitary Cushing's syndrome is not a consideration [5, 17] . At present, there is insufficient evidence to solve this controversy. However, the recommendation to use the overnight 1 mg suppression test seems sound since this test has been extensively employed for screening purposes, while there is less experience with the use of high-dose dexamethasone tests in other settings than the differential diagnosis of Cushing's syndrome.
It has been advocated that a positive suppression test should be confirmed by other tests but it remains unclear what is the most appropriate biochemical evaluation of silent cortisol excess [2] . Some experts require that two concomitant alterations in the tests aimed to study the HPA axis should be demonstrated to qualify a patient for subclinical Cushing's syndrome, in order to circumvent the problem of false positivity of biochemical testing [4, 8] . Different combinations of abnormal tests may be found when the HPA axis is studied in detail [4, [6] [7] [8] 12, 15, 17] and it remains difficult, even with this approach, to diagnose subclinical Cushing's syndrome. The current uncertainty on what strategy is best suited to detect adrenal cortical autonomy might be solved by finding at what point cortisol excess does lead to clinical morbidity or, in other terms, by finding which endocrine alteration is correlated with a particular phenotype that may cause harm to the patient. However, it is presently unclear whether and how subclinical Cushing's syndrome may affect patients' health [2, 3, [14] [15] [16] [17] 30] .
Clinical Consequences
A critical issue is whether subclinical Cushing's syndrome may predispose to diseases such as arterial hypertension, obesity, or diabetes that are classical features of full-blown endogenous hypercortisolism [18] and cluster in the metabolic syndrome [31] . This is biologically plausible since many patients with clinically inapparent adrenal adenoma can be exposed to a chronic, albeit slight, cortisol excess [12, 14, 15, 17, 32] . There are indeed data indicating that some patients with subtle glucocorticoid excess may develop metabolic derangements, including insulin resistance (Table 1) , that may predispose to atherosclerosis and relevant cardiovascular complications [2, 32] . Interestingly, alterations in glucose metabolism and reduced insulin sensitivity are not restricted to patients with subclinical Cushing's syndrome; however, they are more marked in such patients than in those harboring nonfunctioning adenoma [33] [34] [35] . A recent study found that patients with subclinical Cushing's syndrome display an adverse cardiovascular risk profile, determined by the presence of the metabolic syndrome and evidence of accelerated atherosclerosis, as documented by changes in carotid intimal-medial thickness [36] .
However, caution should be taken in generalizing results from series gathered in academic centers: referall bias is an obvious issue since these studies are not population-based and there is the potential for confounding due to their case-control design. The complexity of an accurate matching between patients and controls for the many factors that may affect cardiovascular risk should be also disclosed [32] . Moreover, the prove of an association should not imply a cause and effect relationship. An alternative hypothesis that adrenal incidentaloma may itself be an unrecognized manifestation of the metabolic syndrome could not be ruled out [37] ; however, a causal link between subclinical Cushing's syndrome and insulin resistance is the most plausible explanation for the available data [32] .
Even if it is held that the metabolic syndrome is associated with enhanced all-cause and cardiovascular mortality [38, 39] , evidence of increased morbidity and mortality in patients with clinically inapparent adrenal adenoma, with or without subclinical Cushing's syndrome, is presently lacking [32] . The (scarce) available data suggest that the great majority of patients with adrenal incidentaloma dies of causes not strictly related to the adrenal mass itself but mostly from cardiovascular events [16, 40, 41] .
Osteoporosis is another established consequence of overt cortisol excess [18] , but data on bone mineral density in patients with clinically inapparent adrenal adenoma are controversial. A research group reported that patients with subclinical Cushing's syndrome have reduced bone mass in both eugonadal and hypogonadal subjects [42] [43] [44] , while another research group published conflicting data [45, 46] and, in our study, we did not find any difference in bone mass density between patients and controls, as well as between patients with or without subclinical hypercortisolism [47] . Differences in the devices used to estimate bone density and in selection criteria of either patients or controls, along with the small number of subjects studied, are likely explanations for the divergent results. There is limited evidence that women with subclinical Cushing's syndrome are exposed to a higher risk of vertebral fractures independently of their gonadal status [48] . Longitudinal studies of adequate statistical power are mandatory to estimate the risk of osteoporotic fractures that greatly affect outcome and quality of life.
The risk of progression from subclinical to overt Cushing's syndrome is minimal ( Table 2) . Development of the overt clinical syndrome during follow-up has been observed in a few cases, while occurrence of silent biochemical alterations has been reported in a percentage ranging from 0 to 11% across different studies [12] . Adrenal adenomas of 3 cm or greater are more likely to develop silent hyperfunction than smaller tumors and the risk seems to plateau after 3 to 4 years, even if it does not completely subside [16, 53] . Con- versely, we have also observed spontaneous regression of the alterations of the HPA axis in some patients and this finding suggests that cortisol hypersecretion may have a cyclical pattern [32] . These follow-up studies are possibly affected by ascertainment bias since many series are retrospective, of relative small size and with variable duration of follow-up. The limited and incomplete evidence available precludes making any stringent recommendation for periodic hormonal testing.
Management Strategies
Since an increased frequency of hypertension, central obesity, impaired glucose tolerance, diabetes and hyperlipoproteinemia has been described in patients with subtle glucocorticoid excess, the management of clinically inapparent adrenal adenoma may have a great deal to do with cardiovascular prevention [32] . However, there is not evidence-based demonstration of the long-term complications of incidentally discovered adrenal adenomas and, consequently, the management of such tumors is largely empirical.
The identification of patients with subclinical Cushing's syndrome may provide an opportunity for early treatment of a notoriously dangerous disease, while recent refinements in the field of minimally invasive surgery have rendered adrenalectomy a more tantalizing and easy-to-perform procedure. However, data are insufficient to indicate the superiority of a surgical or nonsurgical approach to manage patients with subclinical hyperfunctioning adrenal cortical adenomas. Either adrenalectomy or careful observation has been suggested as a treatment option in patients with clinically inapparent adrenal adenoma [5, 17, 32] . Patients with subclinical hypercortisolism should receive perioperative glucocorticoids after removal of the functioning mass because they are at risk for hypoadrenalism [1] [2] [3] . However, it is difficult to predict the risk of post-operative adrenal insufficiency on the basis of endocrine and scintigraphic data; thus, a short course of steroid coverage is to be recommended in all patients after adrenalectomy [15] . Steroids should be discontinued after demonstration of an intact HPA axis according to established workup protocols [55] . Guidelines for follow-up of patients who do not undergo adrenalectomy have yet to be defined.
While adrenalectomy has been demonstrated to correct the biochemical abnormalities, its effect on longterm outcome and quality of life is unknown [5] . Preliminary results suggest that adrenalectomy may ameliorate the cardiovascular risk profile of patients with subclinical Cushing's syndrome, but data are still inconsistent [17, 36, 56] . Even if these data will be confirmed in larger prospective series, it is unlikely that any patient with subclinical Cushing's syndrome should benefit from surgery [5, 17, 32] . As previously mentioned, if our aim is to prevent metabolic and cardiovascular events, the performance of surgery in terms of risk, cost and outcome should be compared with the other possible interventions, including life-style changes and pharmacological therapy. An optimal preventive measure should be harmless for patients while (laparoscopic) adrenalectomy has minimal (but not zero) morbidity and mortality. Thus, doing surgery on more people, even a safe procedure, has the potential to cause considerable morbidity, also when considering that experience is critical and there is a learning curve [5] . Conversely, there is ample evidence of the benefits of drug intervention for treating several clinical manifestations of the metabolic syndrome [32] .
Until the risks and benefits of surgical removal of silent hyperfunctioning adrenal adenomas will be elucidated, we should likely elect to surgery patients with subclinical Cushing's syndrome who display diseases potentially attributable to cortisol excess that are of recent onset, or are resistant to medical intervention, or are rapidly decompensating [5, 17, 32] . This strategy is based purely on pragmatism and not evidence. However, the time course of the attendant disorders may be important for the surgical choice because it has been demonstrated that established complications of overt Cushing's syndrome do not fully resolve after successful surgery [57] . Patients who are not candidates to surgery (possibly the majority) should be enrolled in a program of regular and careful follow up to detect, treat and control hypertension, diabetes, dyslipidemia and the other manifestations of the metabolic syndrome [32] . This conservative approach is always wise despite the many uncertainties on the clinical consequences of subclinical Cushing's syndrome since the metabolic syndrome is directly responsible of the cardiovascular risk of patients with clinically inapparent adrenal adenoma.
Conclusions
Modern medicine involves widespread use of technology that is precious in our current practice but may also have unintended consequences, as the serendipitous discovery of an adrenal mass. Notwithstanding that adrenal incidentaloma has been the subject of a steadily growing number of researches in recent years, the criteria for qualifying the state of subclinical cortisol excess remain controversial.
At present, data are insufficient to estimate the outcome of patients with subclinical Cushing's syndrome. It is tempting to speculate that subclinical Cushing's syndrome represents a very mild variant of the syndrome of endogenous glucocorticoid excess sharing similar target organ damages and long-term complications with the full-blown variant. Even if progression to overt glucocorticoid excess is rare, subclinical Cushing's syndrome has the potential to carry an adverse prognosis since evidence is gathering that silent cortisol excess may contribute to develop the phenotype of insulin resistance, thus portending to 222 atherosclerosis and relevant cardiovascular complications. However, a critical issue is whether a precocious diagnosis and treatment is more effective in paucisymptomatic patients and whether the beneficial effects justify the costs incurred. At present, there is no evidence that this subset of patients would always benefit from adrenalectomy.
Additional research is needed to guide practice and it is of primary importance the establishment of prospective studies to appraise the natural history and long-term morbidity of clinically inapparent adrenal adenomas.
